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Antibody titres against Kaposi’s sarcoma associated herpesvirus (KSHV or human herpesvirus 8 (HHV-8)) and Epstein–Barr virus
(EBV) were examined in people who subsequently developed Kaposi’s sarcoma and non-Hodgkin’s lymphoma, within randomised
controlled trials of antiretroviral therapy in adults infected with the human immunodeficiency virus-1 (HIV). For each case of Kaposi’s
sarcoma (n¼189) and each case of non-Hodgkin’s lymphoma (n¼67), which developed after randomisation, one control was
randomly selected from other trial participants, after matching for age, sex, ethnicity, mode of HIV transmission, type of treatment
received and period of follow-up. Using sera taken an average of two and a half years before the diagnosis of cancer, titres of
antibodies against KSHV latent (LANA) and lytic (K8.1) antigens and against EBV (VCA) antigens were investigated in relation to
subsequent risks of cancer by calculating odds ratios (OR) using conditional logistic regression. Latent antibodies against KSHV were
detectable among 38% (72 out of 189) of Kaposi’s sarcoma cases and 12% (23 out of 189) of their controls (OR¼4.4, 95%
confidence intervals (CI) 2.3–8.3, Po0.001). The OR for Kaposi’s sarcoma increased with increasing antilatent KSHV antibody titre
(w
2
1 for trend¼32.2, Po0.001). Lytic antibodies against KSHV were detectable among 33% (61 out of 187) of Kaposi’s sarcoma cases
and 19% (36 out of 187) of their controls (OR¼2.0, 95% CI 1.2–3.4, P¼0.003) and the OR for Kaposi’s sarcoma increased with
increasing antilytic KSHV antibody titre (w
2
1 for trend¼6.2, P¼0.02). Virtually, all cases and controls had anti-EBV antibodies detected
and the OR for non-Hodgkin’s lymphoma associated with a doubling of the anti-EBV antibody titre was estimated to increase by a
multiplicative factor of 1.3 (95% CI 0.9–1.7, P¼0.1). Kaposi’s sarcoma was not associated with antibody levels against EBV (P¼0.4)
and non-Hodgkin’s lymphoma was not associated with antibodies against KSHV (latent P¼0.3; lytic P¼0.5). Adjustment for CD4
count at the time of sample collection made no material difference to any of the results. In conclusion, among human
immunodeficiency virus infected people, high levels of antibodies against KSHV latent and lytic antigens are strongly associated with
subsequent risk of Kaposi’s sarcoma but not non-Hodgkin’s lymphoma. Antibody titre to EBV does not appear to be strongly
associated with subsequent risk of Kaposi’s sarcoma or non-Hodgkin’s lymphoma in HIV infected people.
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The risk of Kaposi’s sarcoma and non-Hodgkin’s lymphoma is
increased in human immunodeficiency virus-1 (HIV) infection
(Beral and Newton, 1998). Both of these tumours are also
associated with a herpesvirus infection: Kaposi’s sarcoma has
been consistently linked with Kaposi’s sarcoma associated
herpesvirus (KSHV or human herpesvirus-8 (HHV-8)), while
non-Hodgkin’s lymphoma has been linked with another gamma-
herpesvirus, the Epstein–Barr virus (EBV) (Boshoff, 1999; Brooks
et al, 1999). However, there are few data from prospective studies
and the role of antibody titres in predicting the subsequent risk of
cancer is unclear. The aim of the research described here was to
investigate using data collected prospectively, the evolution of
antibody responses to KSHV and to EBV in HIV infected
individuals, who subsequently developed Kaposi’s sarcoma or
non-Hodgkin’s lymphoma compared to that in HIV infected
controls without cancer.
MATERIALS AND METHODS
Study population
UK participants in the Concorde (1994), Delta (1996) and Alpha
(1996) randomised controlled trials of antiretroviral therapy for
HIV infection were followed for the development of AIDS-defining
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scancers. Cases were all participants who did not have a tumour at
trial entry, but who subsequently developed Kaposi’s sarcoma
(n¼189) or non-Hodgkin’s lymphoma (n¼67). The diagnosis of
cancer was made at the participating clinical centre according to
criteria used in each of the three clinical trials and all data used in
these analyses were anonymised. No additional histological
confirmation of diagnosis was available for the purposes of this
investigation, nor were any details of the specific subtypes of non-
Hodgkin’s lymphoma available. Further details of the individual
trials can be found elsewhere (Concorde Co-ordinating Commit-
tee, 1994; Delta Co-ordinating Committee, 1996; Alpha Interna-
tional Co-ordinating Committee, 1996).
For each person with incident cancer, a control was randomly
selected from trial participants, who had not developed cancer
after the same period of active follow-up (methods of follow-up are
described in the individual trial reports), after matching by trial,
age group (710 years), sex, HIV transmission group (homosexual,
intravenous drug user, haemophiliac, blood transfusion, other
blood contact or heterosexual), treatment group used in each trial
(zidovudine (AZT) or placebo [Concorde], low-dose or high-dose
didanosine ddI [Alpha], AZT or AZTþddI or AZTþzalcitabine
(ddC) [Delta]), ethnicity (Caucasian, Indian subcontinent, West
Indian, African, other or mixed) and length of time from entry into
the trial until diagnosis of cancer in cases or the same time interval
in controls (73 months).
At least one sample of stored serum was available for all cases
and their matched controls. In general, these were taken at least 6
months before the date of diagnosis of cancer in cases, or at the
same period of follow-up as the cases to whom they were matched
for controls – referred to as pseudo-diagnosis. Sera were stored
centrally at  701C and shipped on dry ice to University College
London for antibody analyses. A proportion of cases and controls
had two serum samples available for testing, taken at different time
points prior to diagnosis.
Laboratory investigations
All serum samples were tested for antibodies against KSHV and
EBV. Assays were performed by investigators, who were blinded to
the identity and personal characteristics of the person from whom
each sample came and specifically if they were a case or a control.
Details of the testing procedure for antibodies against both latent
and lytic KSHV antigens are described elsewhere (Newton et al,
2003a,b; Bourboulia et al, 2004). Briefly, an indirect immuno-
fluorescence assay to detect IgG antibodies against the KSHV
latent nuclear antigen (LANA) encoded by orf73 was used. Serum
samples that were positive for antibodies against latent KSHV
antigens (at a dilution of 1:100 or more) were then tested at
doubling dilutions, starting at 1:100 in order to provide a measure
of anti-KSHV antibody titre. For the detection of anti-lytic KSHV
antibodies, an adapted multiantigenic peptide (MAP) based
enzyme-linked immunoassay against the late phase of KSHV
replication K8.1 protein was used (Lam et al, 2002). Concordant
results were obtained for 78% of 253 controls in whom both assays
were conducted.
For the detection of human IgG antibodies to EBV, all but two
control samples were analysed by indirect immunofluorescence
(IFA) (Akre et al, 1999). Viral capsid antigen (VCA) IgG was
determined with acetone-fixed P3HR-1 cells (Hinuma et al, 1967).
Titres were determined in two-fold dilutions from 1/10
1 to 1/10
4.
Cutoff for positivity was set at titre X40. The titre of the antibody
was taken as the dilution where brightness of fluorescence
appeared to diminish.
Ramos cells (both KSHV and EBV negative cell lines) were used
to test for crossreactivity with antigens from both viruses. No such
reactivity was observed.
CD4 T-lymphocyte counts (measured as described in individual
studies) at, or within, 3 months, of the date of collection of the
sample used in the study, were available for 86% (163 out of 189)
of Kaposi’s sarcoma cases and for 75% (50 out of 67) of non-
Hodgkin’s lymphoma cases and their matched controls. For two
case–control pairs, there were insufficient sera available for testing
for antibodies against KSHV lytic antigens.
Statistical analyses
Statistical analyses were conducted using STATA software (version
7.0; 2001). Odds ratios (ORs) for cancer in relation to anti-HHV-8
and anti-EBV antibody titres were estimated with 95% confidence
intervals (CI) using conditional logistic regression, with and
without adjustment for CD4 count (o200, 200–500, 4501) at the
time of sample collection. Tests for statistical significance of OR
and linear trend were derived from likelihood ratio test statistics.
All P-values are derived from two-sided tests of statistical
significance.
The main analyses included all subjects who had at least one
sample of serum available, taken at least 6 months before the date
of diagnosis of cancer in cases or pseudo-diagnosis in controls. For
those subjects with two serum samples available, the first was used.
Some additional analyses were restricted to individuals for whom
two serum samples were available prior to diagnosis. In relation to
KSHV, latent antibody titres were grouped into negative (at a
dilution of less than 1:100) and positive. Seropositives were
further subdivided into low titre (dilutions of 1:100 to 1:1600),
medium titre (1:3200 to 1:25600) and high titre (1:51200 or
more). These categories were chosen on the basis of results from
previous case–control studies of Kaposi’s sarcoma in relation to
anti-KSHV antibody titres (Sitas et al, 1999; Newton et al,
2003a,b). Kaposi’s sarcoma associated herpesvirus lytic antibodies
were grouped into negative (optical density (OD) o0.84);
indeterminate (low OD 0.84–1.06) and positive (OD41.06). The
seropositives were further subdivided according to the optical
density (medium OD 1.07–1.99 and high OD41.99). In analyses
involving two levels of lytic anti-KSHV antibodies, those with
indeterminate values were grouped together with the negatives.
Since the assays against latent and lytic anti-KSHV antibodies
are measuring responses to different aspects of the viral life cycle,
no attempt was made to combine the results from each one. All but
two subjects had detectable antibodies against EBV and relative
risks were, therefore, estimated in relation to a doubling of titre.
RESULTS
Table 1 shows the distribution of Kaposi’s sarcoma and non-
Hodgkin’s lymphoma cases and their controls, according to the
variables on which they were matched and to the CD4 count at the
time that the first serum sample was taken.
Kaposi’s sarcoma
The analysis of all study participants who had at least one sample
of serum available, taken an average of about two and a half years
prior to cancer diagnosis (or pseudo-diagnosis in controls) is
shown in Table 2 for antibodies against KSHV latent (189 case–
control pairs) and lytic (187 case–control pairs) antigens. Among
those who developed Kaposi’s sarcoma, the prevalence of latent
anti-KSHV antibodies was 38% (72 out of 189) and among their
matched controls it was 12% (23 out of 189; odds ratio (OR)¼4.4,
95% CI¼2.3–8.3, Po0.001). The risk of Kaposi’s sarcoma
increased with increasing latent anti-KSHV antibody titre
(w
2
1¼32.0; Po0.001). Adjustment for CD4 count at time of sample
collection made little difference to the result (w
2
1¼26.0; Po0.001).
Among those who developed Kaposi’s sarcoma, the prevalence of
lytic anti-KSHV antibodies was 33% (61 out of 187) and among
their matched controls it was 19% (36 out of 187; OR¼2.0, 95%
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sTable 1 Distribution of Kaposi’s sarcoma and non-Hodgkin’s lymphoma cases and controls according to the matching variables
Kaposi’s sarcoma Non-Hodgkin’s lymphoma
Cases
(N¼189)
Controls
(N¼189)
Cases
(N¼67)
Controls
(N¼67)
Sex
Males 189 189 61 61
Females 0 0 6 6
Age (years)
o30 33 38 20 15
3 0 – 3 4 5 55 3 1 42 1
35+ 101 98 33 31
HIV transmission group
Homosexual 188 188 12 12
Other
a 1 1 55 55
Study
Concorde 67 67 20 20
Alpha 56 56 17 17
Delta 66 66 30 30
Ethnicity
White 182 180 64 62
Other
b 79 35
Mean time (days) between first blood sample and
date of diagnosis of cancer/pseudo-diagnosis in
controls
923 (standard
deviation (s.d.)
725)
965 (s.d. 713) 957 (s.d. 786) 977 (s.d. 795)
Time between 1st and 2nd sample (years)
o2 5 35 3 3 02 9
2+ 65 65 18 19
NA
c 71 71 19 19
CD4 count (at 1st sample)
500– 33 45 4 14
2 0 0 – 7 48 4 2 92 7
o200 56 34 17 9
NK
d 26 26 17 17
aHeterosexual/i.v. drug user/haemophiliac/blood transfusion/other blood contact/other.
bIndian subcontinent/West Indian-Guyanan/African/other or mixed.
cNA: not applicable.
dNK: not known.
Table 2 Odds ratios (OR) for Kaposi’s sarcoma according to a measure of latent and lytic anti-KSHV antibody titre
Unadjusted Adjusted for CD4 count
a
Titre Number of cases/controls N¼189 OR (95% CI) Number of cases/controls N¼163 OR (95% CI)
Latent anti-KSHV antibodies
Negative 117/166 1.0 99/142 1.0
100–1600 27/11 3.9 (1.7–9.1) 25/10 3.5 (1.4–8.7)
3200–25600 32/9 5.3 (2.3–12.5) 27/9 4.1 (1.7–10.2)
51200+ 13/3 5.7 (1.5–20.9) 12/2 8.7 (1.9–40.4)
w
2(1)¼32, Po0.001 w
2(1)¼26, Po0.001
Unadjusted Adjusted for CD4 count
c
Optical density
b (OD) Number of cases/controls N¼187 OR (95% CI) Number of cases/controls N¼161 OR (95% CI)
Lytic anti-KSHV antibodies
Negative 126/151 1.0 109/128 1.0
Low OD 18/10 2.2 (1.0–5.2) 14/10 1.2 (0.5–3.1)
Medium OD 26/13 2.5 (1.2–5.1) 24/12 2.8 (1.3–6.3)
High OD 17/13 1.4 (0.7–2.9) 14/11 1.4 (0.6–3.2)
w
2(1)¼6.2, P¼0.02 w
2(1)¼4.3, P¼0.04
aAdjusted for CD4 count (o200, 200–500, 500+); the number of participants is fewer because some did not have a CD4 count available from around the time the blood was
collected.
bNegative–optical density (OD) o0.84; low OD 0.84–1.06; medium OD 1.07–1.99 and high OD 2.0+.
cAdjusted for CD4 count (o200, 200–500, 500+).
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sCI¼1.2–3.4, P¼0.003). The risk of Kaposi’s sarcoma increased
with increasing lytic anti-KSHV antibody titre (w
2
1¼6.2; P¼0.02).
Adjustment for CD4 count at time of sample collection made little
difference to the result (w
2
1¼4.3; P¼0.04).
Table 3 shows the OR for Kaposi’s sarcoma according to latent
and lytic anti-HHV8 antibody status, stratified by the time between
sample collection and diagnosis. For both antibody measures,
there were no statistically significant differences in the OR for
Kaposi’s sarcoma, according to the time between sample collection
and diagnosis of cancer.
Two samples of sera from before the development of cancer
were available for 118 cases with Kaposi’s sarcoma and their
matched controls. The mean time between the first and second
blood samples was 766 days (standard deviation 350 days). At the
time of first sample collection, the prevalence of latent anti-KSHV
antibodies was 40% (47 out of 118) among those who developed
Kaposi’s sarcoma and 11% (13 out of 118) among their matched
controls. In the second sample, the prevalence was the same for
cases but higher for controls (40% (47 out of 118) vs 21% (25 out of
118)). Using those who were seronegative in both serum samples
as a comparison group, the risk of Kaposi’s sarcoma was
significantly (Po0.05) higher among those people who were
seropositive in the first sample, irrespective of their serostatus in
the second sample (Table 4). There was no evidence that those who
seroconverted to KSHV latent antibodies in the time between the
first and second samples had a risk of Kaposi’s sarcoma over and
above that of those who remained seropositive throughout the
study period. Similar results were obtained when additionally
adjusted for CD4 count (data not shown).
Of the 118 case–control pairs with two samples of sera, for 116
there was sufficient volume of sera available to test for lytic anti-
KSHV antibodies. At the time of first sample collection, the
prevalence of lytic anti-KSHV antibodies was 23% (27 out of 116)
among those who developed Kaposi’s sarcoma and 15% (17 out of
116) among their matched controls. In the second sample, the
prevalence was 22% (26 out of 116) among cases and 13% in
controls. Using those who were seronegative in both serum
samples as a comparison group, the risk of Kaposi’s sarcoma was
significantly (Po0.05) higher among all other groups (Table 4),
although there was no evidence that those who seroconverted to
KSHV lytic antibodies in the time between the first and second
samples had a risk of Kaposi’s sarcoma over and above that of
those who remained seropositive throughout the study period.
Similar results were obtained when additionally adjusted for CD4
count (data not shown).
In relation to antibodies against EBV-VCA, for a doubling of
titre, the odds ratio for Kaposi’s sarcoma was estimated to increase
by a multiplicative factor of 1.1 (95% CI 0.9–1.2; w
2
1¼0.6, P¼0.4;
Table 3 Odds ratios (OR) for Kaposi’s sarcoma according to the latent (seropositive vs seronegative) and lytic (seropositive vs seronegative/
indeterminate) anti-KSHV antibody status, stratified by the time between first sample collection and diagnosis of cancer
Unadjusted Adjusted for CD4 count
a
Time between sample
collection and diagnosis of
Kaposi’s sarcoma
No. of case–
control pairs
(total¼189)
No. of
seropositive
cases/controls OR (95% CI)
No. of case–
control pairs
(total¼163)
No. of
seropositive
cases/controls
Adjusted OR (95%
CI)
Latent anti-KSHV antibodies
o14 months 62 23/4 7.3 (2.2–24.5) 38 16/3 5.0 (1.4–18.5)
14–42 months 67 26/9 3.8 (1.6–9.4) 65 25/8 4.1 (1.5–11.4)
442 months 60 23/10 4.3 (1.4–12.6) 60 23/10 4.1 (1.4–12.4)
w
2(1)¼0.4, P¼0.6 w
2(1)¼0.04, P¼0.8
Unadjusted Adjusted for CD4 count
a
Time between sample
collection and diagnosis of
Kaposi’s sarcoma
No. of case–
control pairs
(total¼187)
No. of
seropositive
cases/controls OR (95% CI)
No. of case–
control pairs
(total¼161)
No. of
seropositive
cases/controls
Adjusted OR (95%
CI)
Lytic anti-KSHV antibodies
o14 months 60 16/6 2.7 (1.0–6.8) 36 11/4 3.9 (0.9–16.1)
14–42 months 67 17/11 1.8 (0.7–4.2) 65 17/10 2.6 (0.9–7.5)
442 months 60 11/9 1.3 (0.5–3.5) 60 11/9 1.4 (0.5–3.9)
w
2(1)¼1.1, P¼0.3 w
2(1)¼1.4, P¼0.2
aAdjusted for CD4 count (o200, 200–500, 500+); the number of participants is fewer because some did not have a CD4 count available from around the time the blood was
collected.
Table 4 Odds ratios for Kaposi’s sarcoma among those with two serum samples available for testing, according to whether the first and second sample
was sero-positive or negative for latent and lytic anti-KSHV antibodies
Latent antibodies Lytic antibodies
1st sample/
2nd sample
Number of cases/
controls N¼118 OR (95% CI)
Number of cases/
controls N¼116 OR (95% CI)
neg/neg 56/89 1.0 71/92 1.0
neg/pos 15/16 1.5 (0.6–3.5) 16/7 3.8 (1.4–10.0)
pos/neg 15/4 9.6 (2.1–43.5) 17/8 2.7 (1.2–6.0)
Pos/pos 32/9 5.5 (2.6–11.6) 12/9 2.2 (0.9–5.1)
w
2(3)¼27.9, Po0.001 w
2(3)¼11.0, P¼0.01
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sTable 5). After adjustment for CD4 count at the time of sample
collection, this factor was 1.0 (95% CI 0.8–1.2; w
2
1¼0.04, P¼0.8).
Non-Hodgkin’s lymphoma
The prevalence of antibodies against latent KSHV antigens was
15% (10 out of 67) in those with non-Hodgkin’s lymphoma and 9%
(6 out of 67) in their matched controls (OR¼1.8, 95% CI 0.6–5.4;
Table 6). The prevalence of antibodies against lytic KSHV antigens
was 9% (six out of 66) in those with non-Hodgkin’s lymphoma and
6% (four out of 66) in their matched controls (OR¼1.5, 95% CI
0.4–5.3; Table 6).
Among all people with non-Hodgkin’s lymphoma (67 case–
control pairs; for those with two serum samples, the first was
used), for a doubling of anti-EBV antibody titre, the odds ratio for
non-Hodgkin’s lymphoma was estimated to increase by a multi-
plicative factor of 1.3 (95% CI 0.9–1.7; w
2
1¼2.5, P¼0.1; Table 5).
After adjustment for CD4 count at the time of sample collection,
the equivalent factor was 1.5 (95% CI 0.9–2.3; w
2
1¼3.30, P¼0.1).
Two samples of sera were available for 48 cases of non-Hodgkin’s
lymphoma and their matched controls. The mean time between
first and second blood samples was 653 days (standard deviation
382 days). For 13 cases and six controls, the titre of antibodies
against EBV stayed the same in the first and second samples; for 15
cases and 14 controls the titre declined between samples and for 18
cases and 26 controls the titre increased.
DISCUSSION
Among HIV infected people, high levels of antibodies against
KSHV are strongly predictive of the subsequent risk of Kaposi’s
sarcoma, but not of non-Hodgkin’s lymphoma. We find no
significant association between anti-EBV-VCA antibodies and
non-Hodgkin’s lymphoma or Kaposi’s sarcoma in HIV seroposi-
tive adults.
Data from case–control studies (using the same assay against
KSHV latent nuclear antigens encoded by orf73) suggest that high
anti-KSHV antibody titres are associated with an increased risk of
Kaposi’s sarcoma both in HIV seropositive and seronegative
people (Sitas et al, 1999; Davidovici et al, 2001; Newton et al,
2003a,b; Ziegler et al, 2003). Prospective data are lacking, although
a study of HIV infected people in Italy suggested that anti-KSHV
antibody titres may be persistently high even before the diagnosis
of Kaposi’s sarcoma, based on the observation of 21 cases of the
tumour (Rezza et al, 1999). Data presented here confirm, on
substantially larger numbers of cases, that anti-KSHV antibodies
are detectable before the diagnosis of the tumour and that the
subsequent risk of Kaposi’s sarcoma increases with increasing
antibody titres (this is true for latent and lytic antibodies). Since all
study participants were HIV seropositive at entry to the study, we
could not investigate whether the risk of Kaposi’s sarcoma was
higher among those who seroconverted to KSHV after becoming
infected with HIV as compared to before infection with HIV
(Renwick et al 1998; Jacobson et al, 2000). However, we found no
evidence that seroconversion to antibodies against KSHV during
the course of this study was associated with a particularly
increased risk of Kaposi’s sarcoma as compared to people who
had been seropositive for KSHV throughout.
Human immunodeficiency virus-associated non-Hodgkin’s lym-
phomas are atypical and can be divided into three broad categories
on the basis of their clinical, histological and epidemiological
features. The most common subtype in almost all studies is a B cell
immunoblastic lymphoma (Newton et al,1 9 9 9 ) .R o u g h l yh a l fo f
such tumours have been found to contain evidence of EBV DNA in
tumour tissue. Another subtype is Burkitt-type non-Hodgkin’s
lymphoma, which resemble the sporadic form of the disease; about
30% of these tumours have been found to contain EBV-DNA. The
third major subtype is cerebral non-Hodgkin’s lymphoma, almost
100% of which contains evidence of EBV DNA. Precise diagnostic
information on the subtypes of non-Hodgkin’s lymphoma was
unavailable in this study.
In relation to non-Hodgkin’s lymphoma, data from three
prospective studies of people not known to be infected with HIV
suggest that high antibody titres to the EBV VCA are predictive of
an increased risk of the tumour. This is based on observation of 14
cases of Burkitt’s lymphoma in Ugandan children and 115 cases of
other non-Hodgkin’s lymphomas in Europe and the USA (de-The ´
et al, 1978; Mueller et al, 1991; Lehtinen et al, 1993). Results
Table 5 Multiplicative factor by which the odds ratios for Kaposi’s
sarcoma and non-Hodgkin’s lymphoma increased in relation to a doubling
of the anti-EBV antibody titre
Factor (95% CI) Adjusted factor (95% CI)
Kaposi’s sarcoma 1.1 (0.9–1.2) 1.0 (0.8–1.2)
Non-Hodgkin’s lymphoma 1.3 (0.9–1.7) 1.5 (0.9–2.3)
Table 6 Odds ratios for non-Hodgkin’s lymphoma in relation to latent and lytic antibodies against KSHV
Unadjusted Adjusted for CD4
a
Titre Number of cases/controls N¼67 OR (95% CI) Number of cases/controls N¼50 OR (95% CI)
Latent anti-KSHV antibodies
Negative 57/61 1.0– 43/44 1.0–
Positive 10/6 1.8 (0.6–5.4) 7/6 1.2 (0.3–5.3)
w
2(1)¼1.2, P¼0.3 w
2(1)¼0.04, P¼0.8
Unadjusted Adjusted for CD4
a
Titre Number of cases/controls N¼66 OR (95% CI) Number of cases/controls N¼49 OR (95% CI)
Lytic anti-KSHV antibodies
Negative 60/62 1.0– 44/45 1.0–
Positive 6/4 1.5 (0.4–5.3) 5/4 0.5 (0.1–2.7)
w
2(1)¼0.4, P¼0.5 w
2(1)¼ 0.6, P¼0.4
aAdjusted for CD4 count (o200, 200–500, 500+); the number of participants is fewer because some did not have a CD4 count available from around the time the blood was
collected.
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spresented here are the only prospective data on anti-EBV antibody
titres in relation to the development of lymphoma in people known
to be infected with HIV.
As almost everyone studied was seropositive for antibodies
against EBV, comparisons between cases and controls rely on a
quantitative assessment of antibody titre, thereby reducing
statistical power to detect true differences. Furthermore, recent
work by Berrington de Gonzalez et al (submitted) demonstrated
substantial variability in anti-EBV-VCA antibody titres for control
samples, depending on laboratory conditions. The fact that non-
Hodgkin’s lymphoma comprises a heterogeneous group of
diseases, only a proportion of which may be associated with EBV
infection, coupled with variability in assay results, it is likely that a
subtle association would be missed, particularly given the
relatively small number of cases investigated here. Similarly,
laboratory variation in results for antibodies against KSHV
antigens may account for the discordant results found for a
proportion of those individuals who had two samples tested.
In summary, among HIV infected people, high levels of
antibodies against KSHV appear strongly associated with subse-
quent risk of Kaposi’s sarcoma, but not with non-Hodgkin’s
lymphoma. Antibodies against EBV were not strongly associated
with subsequent development of Kaposi’s sarcoma or non-
Hodgkin’s lymphoma.
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